{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:02:12Z","timestamp":1792814532206,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T00:00:00Z","timestamp":1511136000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s40262-017-0603-8","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T05:00:49Z","timestamp":1511154049000},"page":"877-893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach"],"prefix":"10.1007","volume":"57","author":[{"given":"Helena","family":"Colom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc","family":"Andreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A","family":"Hesselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda C. M.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Bestard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Torras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Cruzado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Griny\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3387-5757","authenticated-orcid":false,"given":"N\u00faria","family":"Lloberas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"key":"603_CR1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF02171743","volume":"2","author":"JC Wu","year":"1994","unstructured":"Wu JC. Mycophenolate mofetil: Molecular mechanisms of action. Persp Drug Disc and Design. 1994;2:185\u2013204.","journal-title":"Persp Drug Disc and Design"},{"key":"603_CR2","first-page":"314","volume":"23","author":"A Grailer","year":"1991","unstructured":"Grailer A, Nichols J, Hullett D, Sollinger HW, Burlingham WJ. Inhibition of human B cell responses in vitro by RS-61443, cyclosporine A and DAB486 IL-2. Transpl Proc. 1991;23:314\u20135.","journal-title":"Transpl Proc"},{"issue":"2","key":"603_CR3","first-page":"15","volume":"23","author":"EM Eugui","year":"1991","unstructured":"Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppresive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transpl Proc. 1991;23(2):15\u20138.","journal-title":"Transpl Proc"},{"issue":"5","key":"603_CR4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/tri.12554","volume":"28","author":"T Gelder van","year":"2015","unstructured":"van Gelder T, Hesselink DA. Mycophenolate revisited. Transpl Int. 2015;28(5):508\u201315.","journal-title":"Transpl Int"},{"key":"603_CR5","first-page":"925","volume":"28","author":"RES Bullingham","year":"1996","unstructured":"Bullingham RES, Nicholls AJ, Hale M. Pharmacokinetics of mycophenolate mofetil (RS 61443): A short review. Transpl Proc. 1996;28:925\u20139.","journal-title":"Transpl Proc"},{"issue":"6","key":"603_CR6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RES Bullingham","year":"1998","unstructured":"Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34(6):429\u201355.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"603_CR7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2165\/00003088-200746010-00002","volume":"46","author":"CE Staatz","year":"2007","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):14\u201358.","journal-title":"Clin Pharmacokinet"},{"key":"603_CR8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1681\/ASN.2005101070","volume":"17","author":"RM Hest Van","year":"2006","unstructured":"Van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17:871\u201380.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"603_CR9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2125.2006.02841.x","volume":"63","author":"RM Hest Van","year":"2007","unstructured":"Van Hest RM, Van Gelder T, Bouw R, Goggin T, Gordon R, Mamelok RD, et al. Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol. 2007;63(6):741\u201352.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"603_CR10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/clinchem\/41.7.1011","volume":"41","author":"I Nowak","year":"1995","unstructured":"Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41(7):1011\u20137.","journal-title":"Clin Chem"},{"key":"603_CR11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/dmd.104.001651","volume":"33","author":"N Picard","year":"2005","unstructured":"Picard N, Ratanasavanh D. Premaud, Le Meur Y, Marquet P. Identification of UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33:139\u201346.","journal-title":"Drug Metab Dispos"},{"key":"603_CR12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1124\/dmd.105.006122","volume":"34","author":"IS Westley","year":"2006","unstructured":"Westley IS, Brogan LR, Morris RG, Evans AM, Sallustio BC. Role of MRP2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos. 2006;34:261\u20136.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"603_CR13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/01.tp.0000276936.14041.6c","volume":"84","author":"M Naesens","year":"2007","unstructured":"Naesens M, De Loor H, Vanrenterghem Y, Kuypers DR. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation. 2007;84(3):362\u201373.","journal-title":"Transplantation"},{"issue":"2","key":"603_CR14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/FTD.0b013e31820c0a96","volume":"33","author":"T Gelder van","year":"2011","unstructured":"van Gelder T, Silva HT, de Fijter Budde K, Kuypers D, Mamelok RD, Armstrong VW, et al. How\u00a0delayed graft function\u00a0impacts exposure to mycophenolic acid in patients after renal transplantation. Ther Drug Monit. 2011;33(2):155\u201364.","journal-title":"Ther Drug Monit"},{"issue":"11","key":"603_CR15","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1093\/ndt\/gfr130","volume":"26","author":"N Lloberas","year":"2011","unstructured":"Lloberas N, Torras J, Cruzado JM, Andreu F, Oppenheimer F, S\u00e1nchez-Plumed J, et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients. Results of the pharmacogenomic substudy within the Symphony study. Nephrol Dial Transpl. 2011;26(11):3784\u201393.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"603_CR16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.clpt.2005.06.008","volume":"78","author":"DA Hesselink","year":"2005","unstructured":"Hesselink DA, Van Gelder T. Genetic and non genetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther. 2005;78(4):317\u201321.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"603_CR17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.clpt.2005.06.007","volume":"78","author":"RJ Kuypers","year":"2005","unstructured":"Kuypers RJ, Naesens M, Vermeire S, Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9(UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther. 2005;78(4):351\u201361.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"603_CR18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.clpt.6100073","volume":"81","author":"E Levesque","year":"2007","unstructured":"Levesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, et al. The impact of UGT1A8, UGT1A9 and UGT2B7 genetic polymorphisms on the Pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther. 2007;81(3):393\u2013400.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"603_CR19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/clpt.2009.83","volume":"86","author":"RH Schaik van","year":"2009","unstructured":"van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, et al. UGT1A9\u00a0-275T>A\/-2152C>T\u00a0polymorphisms\u00a0correlate with low MPA exposure and acute rejection in MMF\/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther. 2009;86(3):319\u201327.","journal-title":"Clin Pharmacol Ther."},{"key":"603_CR20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1053-2498(00)00289-8","volume":"20","author":"T Gelder Van","year":"2001","unstructured":"Van Gelder T, Klupp J, Barten MJ, Christians U, Christians U, Morris RE. Co-administration of tacrolimus and mycophenolate mofetil does not increase mycophenolic acid (MPA) exposure, but co-administration of cyclosporine inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure. J Heart Lung Transpl. 2001;20:160\u20131.","journal-title":"J Heart Lung Transpl"},{"key":"603_CR21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00007691-200104000-00005","volume":"23","author":"T Gelder Van","year":"2001","unstructured":"Van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119\u201328.","journal-title":"Ther Drug Monit"},{"key":"603_CR22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/jpet.103.063073","volume":"309","author":"M Kobayashi","year":"2004","unstructured":"Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T. Cyclosporin A but not tacrolimus inhibits the biliary excretion of mycophenlic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029\u201335.","journal-title":"J Pharmacol Exp Ther"},{"key":"603_CR23","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1046\/j.1600-6143.2005.00779.x","volume":"5","author":"DA Hesselink","year":"2005","unstructured":"Hesselink DA, Van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the resistance-associated protein 2. Am J Transpl. 2005;5:987\u201394.","journal-title":"Am J Transpl"},{"key":"603_CR24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0966-3274(97)80042-1","volume":"5","author":"K Zucker","year":"1997","unstructured":"Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol. 1997;5:225\u201332.","journal-title":"Transpl Immunol"},{"key":"603_CR25","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1046\/j.1523-1755.2002.00531.x","volume":"62","author":"D Cattaneo","year":"2002","unstructured":"Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycohenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060\u20137.","journal-title":"Kidney Int"},{"key":"603_CR26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00007691-200102000-00007","volume":"23","author":"L Pou","year":"2001","unstructured":"Pou L, Brunet M, Cantarell C, Vidal E, Oppenheimer F, Monforte V, et al. Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit. 2001;23:35\u20138.","journal-title":"Ther Drug Monit"},{"key":"603_CR27","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1177\/0091270009358084","volume":"50","author":"AS Benichou","year":"2010","unstructured":"Benichou AS, Blanchet B, Conti F, Hornecker M, Bernard D, Taieb F, et al. Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplant period. J Clin Pharmacol. 2010;50:1202\u201310.","journal-title":"J Clin Pharmacol"},{"key":"603_CR28","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1681\/ASN.V981511","volume":"9","author":"LT Weber","year":"1998","unstructured":"Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. J Am Soc Nephrol. 1998;9:1511\u201320.","journal-title":"J Am Soc Nephrol"},{"key":"603_CR29","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/01.ASN.0000027031.79843.6C","volume":"13","author":"LT Weber","year":"2002","unstructured":"Weber LT, Shipkova M, Armstrong VW, Wagner N, Sch\u00fctz E, Mehls O, et al. Pharmacokinetic-pharmacodyanmic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13:759\u201368.","journal-title":"J Am Soc Nephrol"},{"key":"603_CR30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2710.2010.01168.x","volume":"36","author":"Y Mino","year":"2011","unstructured":"Mino Y, Naito T, Otsuka A, Takayama T, Ozono S, Kagawa Y, et al. Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase. J Clin Pharm Ther. 2011;36:217\u201324.","journal-title":"J Clin Pharm Ther"},{"key":"603_CR31","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0009-9236(98)90058-3","volume":"64","author":"MD Hale","year":"1998","unstructured":"Hale MD, Nicholls AJ, Bullingham RE, Hen\u00e9 R, Hoitsma A, Squifflet JP, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672\u201383.","journal-title":"Clin Pharmacol Ther"},{"key":"603_CR32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007890-199907270-00018","volume":"68","author":"T Gelder Van","year":"1999","unstructured":"Van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomised double blind, multicenter plasma concentration study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261\u20136.","journal-title":"Transplantation"},{"key":"603_CR33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00007691-200108000-00001","volume":"23","author":"LM Shaw","year":"2001","unstructured":"Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of roundtable discussion. Ther Drug Monit. 2001;23:305\u201315.","journal-title":"Ther Drug Monit"},{"key":"603_CR34","first-page":"28","volume":"25","author":"Y Meur Le","year":"2001","unstructured":"Le Meur Y, Borrows R, Pescovitz MD, Budde K, Grinyo J, Bloom R, et al. Therapeutic drug monitoring of mycophenolate in kidney transplantation: report of the transplantation society consensus meeting. Transpl Rev. 2001;25:28\u201364.","journal-title":"Transpl Rev"},{"issue":"7","key":"603_CR35","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2165\/11312600-000000000-00000","volume":"48","author":"RM Hest Van","year":"2009","unstructured":"Van Hest RM, Van Gelder T, Vulto AG, Shaw LM, Mathot RA. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal trasnplant recipients. Clin Pharmacokinet. 2009;48(7):464\u201376.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"603_CR36","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10928-009-9136-6","volume":"36","author":"BC Winter de","year":"2009","unstructured":"de Winter BC, Van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite n renal transplant recipients. J Pharmacokinet Pharmacodyn. 2009;36(6):541\u201364.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"603_CR37","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/ndt\/gfp162","volume":"24","author":"JM Griny\u00f3","year":"2009","unstructured":"Griny\u00f3 JM, Ekberg H, Mamelok RD, et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low dose cyclosporine, low dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transpl. 2009;24:2269\u201376.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"603_CR38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.tp.0000200307.79962.48","volume":"81","author":"M Brunet","year":"2006","unstructured":"Brunet M, Cirera I, Martorell J, Vidal E, Mill\u00e1n O, Jim\u00e9nez O, et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation. 2006;81(4):541\u20136.","journal-title":"Transplantation."},{"issue":"2","key":"603_CR39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/FTD.0b013e3182a37a1e","volume":"36","author":"P Langers","year":"2014","unstructured":"Langers P, Press RR, Inderson A, Cremers SC, den Hartigh J, Baranski AG, et al. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation. Ther Drug Monit. 2014;36(2):141\u20137.","journal-title":"Ther Drug Monit"},{"key":"603_CR40","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.0306-5251.2001.01487.x","volume":"52","author":"K Bowalgaha","year":"2001","unstructured":"Bowalgaha K, Miners JO. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol. 2001;52:605\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"603_CR41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF03256246","volume":"11","author":"M Brunet","year":"2007","unstructured":"Brunet M, Campistol JM, Diekmann F, Guillen D, Mill\u00e1n O. T cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy. Mol Diagn Ther. 2007;11(4):247\u201356.","journal-title":"Mol Diagn Ther"},{"key":"603_CR42","volume-title":"NONMEM user\u2019s guide","author":"R Bauer","year":"2011","unstructured":"Bauer R. NONMEM user\u2019s guide. Ellicott City: Icon Development Solutions; 2011."},{"issue":"1","key":"603_CR43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO. Xpose: an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Meth Programs Biomed. 1999;58(1):51\u201364.","journal-title":"Comput Meth Programs Biomed."},{"key":"603_CR44","doi-asserted-by":"crossref","unstructured":"Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Meth Programs Biomed. 2005;79(3):241\u201357.","DOI":"10.1016\/j.cmpb.2005.04.005"},{"key":"603_CR45","unstructured":"Certara LP. Phoenix 6.3.0.395. WinNonlin\u00ae Copyright \u00a9 1998\u20132012."},{"key":"603_CR46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34:711\u201326.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"603_CR47","doi-asserted-by":"crossref","first-page":"E946","DOI":"10.1152\/ajpendo.2001.281.5.E946","volume":"281","author":"N Picard-Hagen","year":"2001","unstructured":"Picard-Hagen N, Gayrard V, Alvinerie M, Smeyers H, Ricou R, Bousquet-Melou A, et al. A nonlabeled method to evaluate cortisol production rate by modelling plasma CBG-free cortisol disposition. Am J Physiol Endocrinol Metab. 2001;281:E946\u201356.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"603_CR48","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/ki.2013.517","volume":"86","author":"H Colom","year":"2014","unstructured":"Colom H, Lloberas N, Andreu F, Cald\u00e9s A, et al. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. Kidney International. 2014;86(6):1434\u201343.","journal-title":"Kidney International"},{"issue":"1","key":"603_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11536640-000000000-00000","volume":"50","author":"CMT Sherwin","year":"2011","unstructured":"Sherwin CMT, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011;50(1):1\u201324.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"603_CR50","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2125.2011.04140.x","volume":"73","author":"CMT Sherwin","year":"2012","unstructured":"Sherwin CMT, Sagcal-Gironella ACP, Fukuda T, Brunner HI, Vinks AA. Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol. 2012;73(5):727\u201340.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"603_CR51","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1365-2125.2008.03109.x","volume":"65","author":"Z Jiao","year":"2008","unstructured":"Jiao Z, Ding JJ, Shen J, Liang HQ, Zhong LJ, Wang Y, et al. Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. Br J Clin Pharmacol. 2008;65(6):893\u2013907.","journal-title":"Br J Clin Pharmacol"},{"key":"603_CR52","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2165\/11318060-000000000-00000","volume":"48","author":"FT Musuamba","year":"2009","unstructured":"Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, et al. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with cyclosporin or sirolimus. Clin Pharmacokinet. 2009;48:745\u201358.","journal-title":"Clin Pharmacokinet"},{"key":"603_CR53","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF01113502","volume":"21","author":"MO Karlsson","year":"1993","unstructured":"Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993;21:735\u201350.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"603_CR54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01117450","volume":"6","author":"T Yamaoka","year":"1978","unstructured":"Yamaoka T, Nakagawa T, Uno T. Application of Akaike\u2019s information criterion (AIC) in the evaluation of linear pharmacokinetics equations. J Pharmacokinet Biopharm. 1978;6(2):165\u201375.","journal-title":"J Pharmacokinet Biopharm."},{"key":"603_CR55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341.","journal-title":"Nephron"},{"issue":"3","key":"603_CR56","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558\u201369.","journal-title":"AAPS J."},{"key":"603_CR57","unstructured":"Holford N. The visual predictive check\u2014superiority to Standard diagnostic (Rorschach) plots. Abstract 738. Pamplona, Spain 2005. p. 14."},{"issue":"2","key":"603_CR58","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"issue":"2","key":"603_CR59","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011555016423","volume":"28","author":"Y Yano","year":"2001","unstructured":"Yano Y, Beal S, Sheiner LB. Evaluating pharmacokinetic-pharmacodynamic models using the posterior predictive check. J Pharmacokinet Biopharm. 2001;28(2):171\u201392.","journal-title":"J Pharmacokinet Biopharm"},{"key":"603_CR60","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL. Some suggestions measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503\u201312.","journal-title":"J Pharmacokinet Biopharm"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-017-0603-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0603-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0603-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T17:27:45Z","timestamp":1659893265000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-017-0603-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1007\/s40262-017-0603-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,20]]}}}